Long-term Maintenance of ≥50% and ≥75% Migraine Response With Eptinezumab in Patients With High-frequency Episodic Migraine and Chronic Migraine and 2-4 Prior Migraine Preventive Treatment Failures (P12-12.005)
{{output}}
Objective: This post hoc analysis of the DELIVER trial evaluated sustained ≥50% or ≥75% migraine responses over 72 weeks of eptinezumab treatment in patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM)... ...
